Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...